The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
Official Title: A Multicenter, Randomized Clinical Investigation of Trelstar Versus Continued Therapy in Patients Receiving Lupron or Zoladex for Advanced Prostate Cancer
Study ID: NCT02749825
Brief Summary: This research study looks at Testosterone levels in patients receiving Trelstar versus those receiving Lupron or Zoladex. These drugs have been approved for treatment of Prostate Cancer by the FDA.
Detailed Description: Patients who are currently receiving Lupron or Zoladex will be consented and then randomized to receive either continued treatment with the drug they have been on, or will be randomized to Trelstar for a period of 3 months. At the end of that period, testosterone and prostate serum antigen (PSA) levels will be drawn and compared to their previous levels to determine if Trelstar is as effective as the previous treatment.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Arizona Urologic Specialists, Tucson, Arizona, United States
Heritage Physician Group - Urology Department, Hot Springs, Arkansas, United States
California Oncology of the Central Valley, Fresno, California, United States
San Bernardino Urological Associates Medical Group, San Bernardino, California, United States
UroSearch, Ocala, Florida, United States
Scott A Slavis, MD, PC, Las Vegas, Nevada, United States
Shaukat M Qureshi, MD, Pennsville, New Jersey, United States
Brooklyn Heights Urology Associates, Brooklyn, New York, United States
Jazrawi-Atallah, P.C., Brooklyn, New York, United States
Albemarle Urology Clinic, PA, Albemarle, North Carolina, United States
Raj P. Chopra MD, PC, Bloomsburg, Pennsylvania, United States
Name: Michael Michael Manyak, MD
Affiliation: Georege Washington University
Role: PRINCIPAL_INVESTIGATOR